December 14, 2021
Life Sciences
  • Pfizer released new data confirming its oral antiviral pill for COVID-19 reduced the risk of hospitalization or death by 89 percent in high-risk adults. The company said there is an ongoing interim analysis of a second study of the pill, called Paxlovid, which has so far shown a 70 percent reduction in hospitalization among standard-risk adults. A key FDA advisory panel endorsed an antiviral pill developed by Merck and Ridgeback Biotherapeutics in late November and is expected to decide soon whether to authorize Paxlovid. (Press release here; Articles here and here)